Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

PetVivo Holdings Inc. (PETV)

  • SEC News
  • Jan. 14, 2026, 18:01 UTC
  • 1
  • 1 comments

(99% Neutral) PetVivo Holdings Inc. (PETV) Announces Executive Departure

Comment Full text

AgeX Therapeutics Inc. (was merged with Biotechnology Serina Therapeutics (NYSE: SER) on 27/04/2024) (AGE)

  • SEC News
  • Jan. 14, 2026, 17:56 UTC
  • 1
  • 1 comments

Moreadith Randall 🟡 adjusted position in 6.5K shares (2 derivative) of Serina Therapeutics, Inc. (SER) at $2.50 Transaction Date: Jan 13, 2026 | Filing ID: 000004

Comment Full text

Perrigo Company plc (PRGO)

  • Business News
  • Jan. 14, 2026, 17:00 UTC
  • 10
  • 1 comments

Deadline Alert: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Market reaction Comment Full text

Smart for Life, Inc. (SMFL)

  • Business News
  • Jan. 14, 2026, 16:36 UTC
  • 9
  • 1 comments

STEM Literacy Project Expands Across North Carolina Collegiate SWE Sections

Market reaction Comment Full text

Cosmos Holdings Inc. (COSM)

  • Business News
  • Jan. 14, 2026, 16:25 UTC
  • 7
  • 1 comments

Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research

Market reaction Comment Full text

Quanterix Corp (QTRX)

  • SEC News
  • Jan. 14, 2026, 16:01 UTC
  • 1
  • 1 comments

Elliott Jeffrey Thomas 🟢 acquired 23.4K shares of Quanterix Corp (QTRX) Transaction Date: Jan 02, 2026 | Filing ID: 000001

Comment Full text

Mesoblast Ltd. (MEOBF)

  • SEC News
  • Jan. 14, 2026, 15:57 UTC
  • 8
  • 0 comments

New Form 424B3 - MESOBLAST LTD Filed: 2026-01-14 AccNo: 0001213900-26-004248 Size: 327 KB

Comment Full text

BridgeBio Pharma (BBIO)

  • Business News
  • Jan. 14, 2026, 15:14 UTC
  • 6
  • 1 comments

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes Due 2033 to Prefund Repayment of Convertible Senior Notes Due 2027

Market reaction Comment Full text

Mainz Biomed (MYNZ)

  • Business News
  • Jan. 14, 2026, 14:29 UTC
  • 6
  • 1 comments

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Market reaction Comment Full text

Oncolytics Biotech Inc (ONCY)

  • Business News
  • Jan. 14, 2026, 14:12 UTC
  • 10
  • 1 comments

A New Press Release from Oncolytics Biotech, Inc

Market reaction Comment Full text

Sigyn Therapeutics Inc. (SIGY)

  • SEC News
  • Jan. 14, 2026, 14:11 UTC
  • 8
  • 0 comments

New Form SCHEDULE 13G/A - Sigyn Therapeutics, Inc. Filed: 2026-01-14 AccNo: 0001213900-26-004186 Size: 11 KB

Comment Full text

Femasys Inc (FEMY)

  • Business News
  • Jan. 14, 2026, 14:02 UTC
  • 9
  • 1 comments

- Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Market reaction Comment Full text

Apollo Medical Holdings Inc (AMN)

  • SEC News
  • Jan. 14, 2026, 14:01 UTC
  • 1
  • 1 comments

(35% Negative) Apollo Medical Holdings Inc (AMN) Reports Q1 2026 Financial Results

Comment Full text

Nexalin Technology Inc (NXLIW)

  • Business News
  • Jan. 14, 2026, 14:00 UTC
  • 9
  • 1 comments

Published Peer-Reviewed Study Demonstrates NexalinsDIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Market reaction Comment Full text

Adial Pharmaceuticals Inc (ADIL)

  • Business News
  • Jan. 14, 2026, 14:00 UTC
  • 8
  • 1 comments

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

Market reaction Comment Full text
  • Previous
  • 149
  • 150
  • 151
  • 152
  • 153
  • Next

Search

News categories

  • Technical Exchange News(10870)
  • Event(2243)
  • SEC News(189155)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(124508)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin